Characterization and predictors of sleep disturbance in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

被引：0
|
作者：
Westbrook, Travis D.
Maddocks, Kami J.
Andersen, Barbara L.
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18021
引用
收藏
页数：1
相关论文
共 50 条
  • [41] NURSING IMPLICATIONS FOR VENETOCLAX USE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MULTICENTER ANALYSIS
    Kennard, Kaitlin
    Howlett, Christina
    Timberg, Mary
    Staller, Emma
    Varga, Julia
    Dorsey, Colleen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [42] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [43] Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities
    Ferrajoli, Alessandra
    Keating, Michael J.
    Wierda, William G.
    O'Brien, Susan M.
    Padmanabhan, Swaminathan
    Czuczman, Myron S.
    Chanan-Khan, Asher A.
    BLOOD, 2007, 110 (11) : 232A - 232A
  • [44] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Brown, Jennifer R.
    Hillmen, Peter
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Wu, Kenneth
    Novotny, William
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S266 - S266
  • [45] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Jurczak, Wojciech
    Elmusharaf, Nagah
    Fox, Christopher P.
    Townsend, William
    Paulovich, Amanda G.
    Sharma, Shringi
    Parr, Graeme
    Munugalavadla, Veerendra
    Krantz, Fanny
    Yang, Helen
    Dean, Emma
    Manwani, Richa
    Hillmen, Peter
    CANCER RESEARCH, 2022, 82 (12)
  • [46] Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.
    Mato, Anthony R.
    Sharman, Jeff P.
    Biondo, Juliana
    Wu, Mei
    Mun, Yong
    Kim, Su Young
    Humphrey, Kathryn
    Boyer, Michelle
    Zhu, Qian
    Seymour, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S220 - S221
  • [48] UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.
    Piris-Villaespesa, M.
    Chavez, J.
    Dalia, S.
    Veliz, M.
    Lancet, Jeffrey
    Bello, C.
    Turba, E.
    Shah, B.
    Komrokji, R.
    Sokol, L.
    Locke, F.
    Kharfan-Dabaja, M.
    Sotomayor, E.
    Pinilla-Ibarz, J.
    HAEMATOLOGICA, 2013, 98 : 46 - 46
  • [49] Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.
    Woyach, Jennifer Ann
    Rogers, Kerry Anne
    Bhat, Seema Ali
    Blachly, James Stewart
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed M.
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng Seok
    Min Hui Wang
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara
    Hillmen, Peter
    D'Rozario, James
    Assouline, Sarit
    Owen, Carolyn
    Robak, Tadeusz
    de la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Lamanna, Nicole
    Verdugo, Maria E.
    Punnoose, Elizabeth A.
    Jiang, Yanwen
    Wang, Jue
    Boyer, Michelle
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kater, Arnon P.
    BLOOD, 2018, 132
12345